Pamela A Pavco

This inventor holds 13 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Phio Pharmaceuticals Corp., Rxi Pharmaceuticals Corporation. Active years: 2014-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pamela A Pavco. Retrieved from https://idiyas.com/inventor/pamela-a-pavco

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 4)

% Patents Active = 69.2

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 6.9

ph-index = 9

Forward Citations = 281(Granted Patents)

Company Filing History:

7 out of 24

Phio Pharmaceuticals Corp.

patents

6 out of 16

Rxi Pharmaceuticals Corporation

patents

Years Active: 2014-2023

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11584933 - RNA interference in ocular indications (2023-02-21),

2. 11001845 - Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) (2021-05-11),

3. 10913948 - RNA interference in dermal and fibrotic indications (2021-02-09),

4. 10815485 - RNA interference in skin indications (2020-10-27),

5. 10662430 - RNA interference in ocular indications (2020-05-26),

6. 10633654 - Modified RNAi polynucleotides and uses thereof (2020-04-28),

7. 10184124 - RNA interference in ocular indications (2019-01-22),

8. 10131904 - Modified RNAi polynucleotides and uses thereof (2018-11-20),

9. 9963702 - RNA interference in dermal and fibrotic indications (2018-05-08),

10. 9938530 - RNA interference in skin indications (2018-04-10),

11. 9340786 - RNA interference in dermal and fibrotic indications (2016-05-17),

12. 9303259 - RNA interference in skin indications (2016-04-05),

13. 8664189 - RNA interference in skin indications (2014-03-04),

Title: The Innovative Contributions of Pamela A. Pavco

Introduction

Pamela A. Pavco is a prominent inventor based in Longmont, Colorado, who has made significant strides in the field of biotechnology. With an impressive portfolio of 13 patents, her work primarily focuses on RNA interference and molecular therapies aimed at treating serious genetic conditions.

Latest Patents

Among her latest inventions, Pamela has developed groundbreaking methods for ocular administration of sd-rxRNA and rxRNAori molecules. This innovation offers new avenues for targeted treatment in ocular indications. Additionally, she has created nucleic acid molecules that target superoxide dismutase 1 (SOD1), which play a crucial role in developing therapeutic strategies for amyotrophic lateral sclerosis (ALS). This invention outlines methods for administering an effective amount of nucleic acid aimed at patients suffering from this debilitating condition.

Career Highlights

Over her career, Pamela has worked with notable companies such as Phio Pharmaceuticals Corporation and Rxi Pharmaceuticals Corporation. Her contributions have been invaluable in advancing the understanding and application of RNA technologies in the pharmaceutical industry.

Collaborations

Pamela has collaborated with esteemed colleagues in her research, including Anastasia Khvorova and William Salomon. These partnerships have fostered innovation and have led to important discoveries in RNA interference and genetic therapies.

Conclusion

Pamela A. Pavco's contributions to the field of biotechnology through her innovative inventions are significant. Her work continues to inspire advancements in treatment methodologies for serious illnesses, and her collaborations reflect the cooperative spirit that drives innovation in scientific research. As her patents illustrate, she is dedicated to making a lasting impact in the field of medicine.

Profile summary based on public USPTO records.